

PHOTOSOFT™ TECHNOLOGY DATA PRESENTED TO LORNE CANCER CONFERENCE

MELBOURNE (AUSTRALIA) 14 February 2020: Invion Limited (ASX: IVX) ("Invion" or "Company"), a drug development company, is pleased to announce that its research partner, Hudson Institute of Medical Research, conducted a poster presentation on the Photosoft™ technology at the highly regarded Lorne Cancer Conference last evening.

Hudson presented the pre-clinical trial results announced to the market on 27 November 2019, as well as additional scientific details of its studies using the Photosoft™ technology in ovarian cancer cell lines and in mice with ovarian cancer.

Key details included in the presentation:

- When exposed to light at 652nm, Photosoft™ was immediately activated and efficiently produced singlet oxygen, which killed cancer cells;
- Photosoft™ was cleared rapidly from cells, which minimised the side effects of phototoxicity;
- Unlike several other sensitisers tested, Photosoft™ had no observable "dark toxicity" in the absence of light activation;
- When injected into the mouse ovarian cancer model, Photosoft™ localised rapidly to tumour tissue and was retained in tumour tissues (but not healthy tissue) for at least 48 hours;
- Photosoft™ activation resulted in substantial inflammation and necrosis of tumour tissue after two days and there was an increase in immune cells after three weeks with the tumour burden reduced by >50% after three weeks.

The annual Lorne Cancer Conference, which runs from 13th February to 15th February, is attended by over 300 leading cancer researchers and academics from Australia and around the world, and is regarded as one of the most prestigious events of its kind in the country.

This is the 32nd year for the conference, which is held at the Cumberland Resort in Lorne, Victoria.

"Invion is delighted that the Hudson Institute presented the findings of its pre-clinical study using the Photosoft™ technology to so many highly regarded leaders in cancer research" said Invion's Chief Executive Officer, Craig Newton.

"This is an exciting period for Invion as we are on track to achieve several key milestones in 2020. This includes the start of human trials using the Photosoft™ technology to treat basal cell carcinoma, which is the most common form of skin cancer and most frequently occurring form of all cancers."

Investor enquiries

Managing Director & CEO, Craig Newton

T: +61 3 9081 6005

E: investor@inviongroup.com

Media enquiries

Brendon Lau

T: 0409 341 613

E: brendon@vantagepointpartners.com.au

ASX ANNOUNCEMENT

About Invion

Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement has been authorised for release by MD & CEO, Craig Newton. **For further information please contact investor@inviongroup.com.**

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.